RIM
NBIX icon

Redwood Investment Management’s Neurocrine Biosciences NBIX Stock Holding History

Redwood Investment Management’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-10,826
Closed -$1.36M – 321
2025
Q2 		$1.36M Buy
+10,826
New +$1.24M 0.14% 204
2024
Q2 		– Sell
-4,652
Closed -$642K – 364
2024
Q1 		$642K Buy
+4,652
New +$635K 0.06% 255

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Redwood Investment Management's NBIX Position: Q3 2025 in Review

Redwood Investment Management sold out of Neurocrine Biosciences (NBIX) in Q3 2025, closing a stake of 10,826 shares — an estimated $1.36M sold.

Redwood Investment Management first reported a position in NBIX in Q1 2024 and held it in 2 quarters. The position peaked at $1.36M in Q2 2025. 650 funds tracked by Wall St. Rank hold NBIX as of Q3 2025.

  • Redwood Investment Management reported no remaining Neurocrine Biosciences position as of Q3 2025 after selling out during the quarter.
  • Redwood Investment Management sold 10,826 Neurocrine Biosciences shares in Q3 2025, an estimated $1.36M.
  • Redwood Investment Management first reported a position in Neurocrine Biosciences in Q1 2024 and held it in 2 quarters.
  • Redwood Investment Management's Neurocrine Biosciences position peaked at $1.36M in Q2 2025.
  • 650 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q3 2025.

Based on Redwood Investment Management's 13F filing for Q3 2025, filed 14 Nov 2025.